Sergio Antón-Fuente - JoVE Visualize

Showing results (1-10 of 3) with videos related to

Pageof 1

Sort By:

Neurology and Therapy|August 12, 2025

Beyond Efficacy: Persistence, NEDA, and Therapeutic Decision-Making in First-Line Multiple Sclerosis TreatmentClara Helena López-Caneda, Sergio Antón-Fuente, Maria José Pérez-Haro, et al.

European Urology Open Science|June 15, 2026

PSA Response as a Prognostic Marker in Metastatic Hormone-sensitive Prostate Cancer: Comparison with Tumor Volume (CHAARTED)Rocío Martínez-Corral, Pedro De Pablos-Rodríguez, Sergio Antón-Fuente, et al.

Urologic Oncology|November 8, 2025

PSA response to predict progression in metastatic hormone-sensitive prostate cancer (mHSPC) patients. When is the optimal time point?Rocío Martínez-Corral, Daniel Pérez-Fentes, Celia Bardella-Altarriba, et al.

Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:

Pageof 1

Neurology and Therapy|August 12, 2025

Beyond Efficacy: Persistence, NEDA, and Therapeutic Decision-Making in First-Line Multiple Sclerosis TreatmentClara Helena López-Caneda, Sergio Antón-Fuente, Maria José Pérez-Haro, et al.

European Urology Open Science|June 15, 2026

PSA Response as a Prognostic Marker in Metastatic Hormone-sensitive Prostate Cancer: Comparison with Tumor Volume (CHAARTED)Rocío Martínez-Corral, Pedro De Pablos-Rodríguez, Sergio Antón-Fuente, et al.

Urologic Oncology|November 8, 2025

PSA response to predict progression in metastatic hormone-sensitive prostate cancer (mHSPC) patients. When is the optimal time point?Rocío Martínez-Corral, Daniel Pérez-Fentes, Celia Bardella-Altarriba, et al.

Pageof 1